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Replication rateAutologous HIV-1-speciﬁc neutralizing antibodies (NAbs) seem unable to inhibit viral replication as they
rapidly select for neutralization escape variants. However, NAbs could potentially contribute indirectly to the
control of HIV-1 if changes in the viral envelope coinciding with NAb escape would impair viral replication
ﬁtness. Here we analyzed the replication kinetics of HIV-1 isolated over the course of infection from ﬁve
typical progressors, three of whom developed strong autologous neutralizing humoral immunity. Viral
replication rate did not correlate with viral sensitivity to autologous serum neutralization or with envelope
length or number of potential N-linked glycosylation sites in gp120, suggesting that the ﬂexibility of the viral
envelope allows escape from NAbs without the loss of viral ﬁtness. Interestingly, the appearance of rapidly
replicating viruses late in infection correlated with lower CD4+ T-cell counts, suggesting that this viral
characteristic may be positively selected when the availability of target cells becomes limiting.
© 2009 Elsevier Inc. All rights reserved.Introduction
Upon infectionwith human immunodeﬁciency virus type 1 (HIV-1),
the majority of individuals develop a potent autologous neutralizing
antibody (NAb) response directed against the envelope glycoprotein
(Env). The understanding of the impact of the autologous NAb response
on the control of virus replication remains incomplete. Due to the rapid
selection of antibody escape variants, NAbs generally lack the ability to
inhibit contemporaneous viruses (Albert et al., 1990; Arendrup et al.,
1992; Bunnik et al., 2008; McKeating et al., 1989; Moore et al., 2009;
Richman et al., 2003; Rong et al., 2009; Von Gegerfelt et al., 1991;
Watkins et al., 1993; Wei et al., 2003). The humoral immune response
therefore seems ineffective in directly inhibiting virus replication.
However, long-term non-progressors (LTNPs) were shown to have
broader and more potent NAb responses than progressors (Cao et al.,
1995; Cecilia et al., 1999; Zhang et al., 1997), although other studies did
not conﬁrm this ﬁnding (Bailey et al., 2006; Harrer et al., 1996).
Moreover, the development of anti-simian immunodeﬁciency virus
(SIV) humoral immunity was found to be critical for the control of SIV
infection in a macaque model (Miller et al., 2007). These observations
suggest that, although NAbs may not be able to directly inhibit
replication of HIV-1, disease progression may be inﬂuenced by the
development of a potent autologous NAb response.tal Immunology at M01-120,
terdam, The Netherlands. Fax:
uitemaker).
ll rights reserved.Mechanisms by which HIV-1 can obtain resistance to antibody
neutralization include extensions of the variable loops of Env (Bunnik
et al., 2008; Sagar et al., 2006), possibly to protect underlying,
conserved regions from antibody recognition (Gray et al., 2007), and
an increase in the density of the envelope glycan shield (Bunnik et al.,
2008; Sagar et al., 2006; Wei et al., 2003). These large alterations in
the length of the variable loops and the glycosylation level of Env are
indicative of the strong selective pressure exerted on the protein by
NAbs. We have previously observed that changes in the length of the
variable loops and the level of glycosylation revert in later stages of
infection (Bunnik et al., 2008), when selection pressure may be lost
due to an impairment of host immunity. Moreover, NAb-driven
changes in Env (partially) revert upon transmission, which renders
the recipient virus neutralization sensitive, although this may not be
true for all subtypes of HIV-1 and/or all modes of transmission
(Chohan et al., 2005; Derdeyn et al., 2004; Li et al., 2006; Sagar et al.,
2009). Similarly, reversion of CTL escape mutations also occurs upon
transmission of HIV-1 to an HLA class I-mismatched recipient, the rate
of which is associated with the cost of the speciﬁc mutation to viral
ﬁtness (Li et al., 2007; Loh et al., 2007). The observation that HIV-1
Env reduces its epitope-masking mechanisms in the absence of
humoral immune pressure may thus indicate that escape from NAbs
inﬂuences the replicative ﬁtness of HIV-1. The development of a
potent autologous NAb response may in this way contribute to
indirect control of virus replication.
We previously reported on the changes in length and glycosylation
of gp120 that coincided with escape from autologous neutralizing
immunity in a longitudinal study on ﬁve participants of the
Amsterdam Cohort Studies with varying humoral immune responses.
225E.M. Bunnik et al. / Virology 397 (2010) 224–230In our present study, we analyzed the effect of escape from autologous
humoral immunity on the replication kinetics of HIV-1 and correlated
the observed changes in length and glycosylation of gp120 of viruses
isolated from these ﬁve individuals with the viral replication rate,
both early in infection, when escape from NAbs occurred, as well as
late in infection, when reversion of the changes induced by NAbs
escape was observed. In addition, we investigated the inﬂuence of
other selective processes on the replication rate of late-stage HIV-1.
Results
Replication kinetics of HIV-1 over the course of infection
We investigated whether changes in Env that related to escape
from autologous neutralizing humoral immunity inﬂuenced the
replication kinetics of HIV-1, using virus variants that were isolated
at multiple time points during infection from ﬁve typical progressors
of the ACS. In a previous study, we determined that individuals H1, H2,
and H3 developed high-titer autologous neutralizing activity, which
decreased in potency in the chronic phase of infection (Bunnik et al.,
2008). Patients H4 and H5, in whom autologous neutralizing serum
activity was not detected, were also included in this study to be able to
distinguish between the effect of escape from NAbs and the effect of
other selective processes on viral replication rates. All patients
received antiretroviral (mono)therapy for various periods of time
over the course of infection (Bunnik et al., 2008), selecting for drug
resistance mutations in pol that have been described to reduce viral
replication ﬁtness (Harrigan et al., 1998; Harrigan et al., 2000) (data
not shown). To exclude an effect of these drug resistance mutations
and of additional mutations in other genes than env on the viralFig. 1. Replication kinetics and molecular characteristics of gp120 of viruses isolated over t
chimeric NL4-3/Env variants expressed as the cumulative p24 production at day 4 after infec
to NAb pressure are indicated in grey. Data were analyzed using a t test for independent sa
variants over the course of infection. Increases and decreases in the length of number of PNGS
horizontal bars represent the means. D.p.i, days post-infection; aa, amino acids; PNGS, potereplication rate, we generated a panel of chimeric NL4-3 viruses, in
which the original envelope was replaced with the envelopes of virus
variants that were isolated from our ﬁve patients. For each time point,
envelopes from a minimum of 2 and a maximum of 8 viruses were
analyzed.
We determined the in vitro replicative capacity of HIV-1 over the
course of infection expressed as the cumulative p24 production at day
4 after inoculation of PHA-stimulated PBMCs with the various
chimeric NL4-3/Env variants. In all patients, the average replication
rates of HIV-1 variants present at a certain time point changed over
the course of infection, although different patterns of change were
observed. For patients H1 and H4, viruses that had been isolated
during the asymptomatic phase of infection, at 42 months and
93 months after seroconversion, respectively, had increased replica-
tion kinetics compared to viruses that had been isolated relatively
early in infection (Fig. 1A). In contrast, replication rates of viruses
from patient H3 declined in this phase of asymptomatic infection,
while replication kinetics of viruses from patients H2 and H5
remained the same. For viruses from patient H1, the increase in
replication kinetics early in infection was followed by a decrease in
replication rate in the later stages of disease, which was not observed
for patient H4 (Fig. 1A). Finally, for patients H2, H3, and H5, the
replication rate of late-stage virus variants was increased compared to
viruses isolated at earlier time points (Fig. 1A).
Escape from autologous humoral immunity is not associated with a
decrease in viral replicative capacity
Previously, we determined that patients H1, H2, and H3 developed
strong autologous neutralizing activity, which decreased in potencyhe course of infection from ﬁve typical progressors. (A) Replication rates of individual
tion of PHA-stimulated PBMC. The time points at which viruses were likely to be subject
mples. (B) The length of gp120 and (C) the number of PNGS in gp120 of clonal HIV-1
over time are indicated by dark grey and light grey areas, respectively. In all panels, the
ntial N-linked glycosylation sites; SC, seroconversion.
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these patients were not neutralized by sera from the same time point
or from earlier time points, suggestive of viral escape from
neutralizing humoral immunity. The time points at which viruses
were likely to be subject to NAb pressure (i.e., time points when
viruses were sensitive to autologous serum neutralization and/or had
escaped from the neutralizing activity elicited in response to virus
variants from the previous time point) are indicated by grey-shaded
areas in Fig. 1A. We ﬁrst analyzed whether escape from the
autologous NAb response was accompanied by a decrease in
replicative ﬁtness. Fig. 1A shows that the replicative capacity of
viruses from patient H3 decreased during the ﬁrst three time points,
coinciding with the presence of autologous neutralizing activity.
However, for patient H3 as well as for patients H1 and H2, the
sensitivities of individual clonal HIV-1 variants for autologous serum
from both the contemporaneous and the subsequent time point
(expressed as 50% inhibitory concentrations) did not correlate with
the replication rates of the corresponding chimeric NL4-3/Env
variants (data not shown).
Escape from autologous neutralizing humoral immunity coincided
with an increase in the length of the variable loops and the number of
PNGS in envelope (Figs. 1B and C) (Bunnik et al., 2008), although
differences in neutralization sensitivity between viruses from the
same time point could not be explained by variations in the envelope
length or the number of PNGS. Moreover, changes in the length of the
variable loops and the number of PNGS in Env were also observed in
viruses from patients H4 and H5, who did not develop a detectable
autologous NAb response, albeit that both masking mechanisms
remained at a lower level in viruses from these patients as compared
to viruses from patients H1, H2, and H3 (Figs. 1B and C). To study
whether the increased protection of the viral envelope against
autologous humoral immunity is associated with a reduction in the
replicative capacity of HIV-1, we correlated the length and the
number of PNGS in gp120 from virus variants that were isolated in the
early phase of infection of patients H1, H2, and H3, when humoral
immunity could be detected, to the replication rates of the
corresponding chimeric NL4-3/Env variants. In patients H1 and H2,
length and glycosylation characteristics of gp120 were not associated
with the viral replication rate (Figs. 2A and B). In contrast, a signiﬁcant
negative correlation was observed between both the length of gp120Fig. 2. Replication kinetics of HIV-1 upon escape from the autologous NAb response. Correlat
variants expressing Env of viruses isolated from patients who developed strong autologous
Correlations were evaluated using the Spearman's rank test. Aa, amino acids; PNGS, potentand the number of PNGS in gp120 of viruses isolated during the ﬁrst
part of infection from patient H3, and the replication kinetics of the
corresponding chimeric NL4-3/Env variants (Figs. 2A and B).
However, it should be mentioned that the chimeric NL4-3 variants
expressing Env from viruses isolated at the earliest time point from
patient H3 replicated exceptionally rapid compared to NL4-3 variants
expressing early Envs from the other patients. The subsequent decline
in replication rate to relatively normal levels, which coincided with
increases in gp120 length and the number of PNGS in this gene, may
thus have been driven by other selective processes than escape from
NAbs. Of note, increases in length and glycosylation characteristics of
Env also occurred in viruses of patients H4 and H5, albeit to lower
levels, and were for HIV-1 variants from these patients also not
correlated with replication rate (data not shown).
Increased viral replication kinetics in late-stage disease
In most patients, changes in Env that coincided with escape from
NAb pressure early in infection reverted during later disease stages
(Figs. 1B and C) (Bunnik et al., 2008). To investigate whether this
reversion of envelope masking mechanisms allowed higher levels of
replication, we correlated the envelope length and glycosylation
characteristics of viruses that had been isolated at four time points
late in infection to the replication rate of the corresponding chimeric
NL4-3/Env variants. In patients H1 and H4, replication rates of late
chimeric NL4-3/Env variants were similar compared to chimeric NL4-
3 variants expressing Envs isolated from earlier time points and, as a
consequence, did not correlate with the envelope length or the
number of PNGS in gp120 (data not shown). In contrast, the
replication rates of chimeric NL4-3 variants expressing Envs from
viruses isolated late in infection from patients H2, H3, and H5 showed
increased replication kinetics compared to earlier NL4-3/Env variants.
In patients H2 and H5, this increased replication rate of late-stage
virus variants was negatively correlated with both the length and the
number of PNGS in gp120 (Figs. 3A and B).
Increased replication of late-stage viruses coincides with low CD4 counts
Previous studies have shown that the replication ﬁtness of R5
viruses isolated during late-stage disease is increased (Etemad et al.,ion between the cumulative production of p24 at day 4 after infection of chimeric NL4-3
humoral immunity, and the length of gp120 (A) or the number of PNGS in gp120 (B).
ial N-linked glycosylation sites; d.p.i, days post-infection.
Fig. 3. Replication kinetics of HIV-1 in relation to molecular characteristics of gp120 in during chronic infection. Correlation between the cumulative production of p24 at day 4 after
infection of chimeric NL4-3 variants expressing Env from viruses isolated during the last four time points of infection, and the length of gp120 (A) or the number of PNGS in gp120
(B). Correlations were analyzed using the Spearman's rank test. Aa, amino acids; PNGS, potential N-linked glycosylation sites; d.p.i, days post-infection.
227E.M. Bunnik et al. / Virology 397 (2010) 224–2302009; Repits et al., 2005; Repits et al., 2008; Sterjovski et al., 2007).
Here, we could conﬁrm this observation for viruses from patients H2,
H3, and H5, while chimeric NL4-3 variants expressing Env from
viruses isolated during the later disease stages from patients H1 and
H4 did not exhibit enhanced replication rates. To understand this
observation and to examine whether other factors than decreased
envelope masking mechanisms may explain the enhanced replication
rate of late-stage viruses from patients H2, H3, and H5, we plotted the
CD4+ T-cell counts of all patients over their course of infection. In
patients H1 and H4, the CD4+ T-cell counts remained above 100 cells/
μl blood, while the appearance of rapidly replicating virus variants in
patients H2, H3, and H5 coincidedwith a CD4+ T-cell count below 100
cells/μl blood (Fig. 4). Although this threshold of 100 CD4+ T cells/μl
blood was chosen arbitrarily, these results indicate that the increased
replication kinetics of HIV-1 may result from the adaptation of the
virus to replicate in the presence of extremely low numbers of target
cells.
Discussion
The impact of the autologous NAb response on HIV-1 disease
progression remains incompletely understood. As HIV-1 rapidly
escapes from autologous humoral immunity, NAbs are not able to
directly inhibit the spread of the virus. However, if escape from NAbs
would result in a decrease in viral ﬁtness, analogous to what isFig. 4. CD4+ T-cell counts over the course of infection. The horizontal dashed line is drawn at
triangles indicate time points during symptomatic disease at which time CD4+ T-cell counts
symptomatic disease at which time CD4+ T-cell counts are below 100 (patients H2, H3, anobserved for certain CTL escape mutations (Friedrich et al., 2004;
Leslie et al., 2004), strong autologous humoral immunity could
contribute indirectly to the control of virus replication. In this study,
we investigated whether escape of HIV-1 from the autologous NAb
response coincided with changes in viral replication kinetics.
In general, the replication rates mediated by Envs of HIV-1 variants
isolated from individuals who developed strong autologous humoral
immunity did not correlate with the sensitivities of these viruses for
autologous serum or with molecular characteristics of Env that have
been associated with NAb escape. Although it should be mentioned
that these results were obtained using a relatively small study cohort,
the absent correlation between escape fromNAbs and viral replication
ﬁtness may suggest that the development of a potent NAb response
does not result in the control of viral replication. Indeed, the plasma
viral loads in patients H1, H2, and H3, who all developed an
autologous NAb response, were not lower as compared to patients
H4 and H5, in whom neutralizing activity in serum was not detected
(Bunnik et al., 2008). These observations are in agreement with recent
studies showing that the development of a broad NAb response does
not inﬂuence disease progression (Euler et al., in press; Piantadosi et
al., 2009). The previously observed presence of strong humoral
immunity in LTNPs is thereforemore likely a consequence of preserved
immune surveillance rather than a cause of non-progression.
Our current data show that the replication kinetics of HIV-1 do not
change upon escape from the autologous NAb responses. This may100 CD4+ T cells/μl blood. Time points of virus isolation are depicted by triangles. Open
are above 100 (patients H1 and H4), while closed triangles represent time points during
d H5).
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against the variable loops in envelope in which a high degree of
sequence variation may be allowed without impairment of the viral
replication ﬁtness. In addition, we have previously shown that HIV-1
resistance to broadly neutralizing monoclonal antibodies b12, 2G12,
2F5, and 4E10 did also not coincide with lower replication rates as
compared to the replication kinetics of neutralization sensitive viruses
(Quakkelaar et al., 2007a). These ﬁndings suggest that the ﬂexibility of
the viral envelope allows escape from NAbs by the introduction of
changes in the sequence or conformation of both its variable and
conserved regions, possibly in combination with compensatory
mutations, without the loss of viral ﬁtness.
Early in infection in patient H3, and late in infection in patients H2
and H5, the length and number of PNGS in gp120 correlated with the
viral replication rate, indicating that the replication kinetics of HIV-1
may under certain circumstances be facilitated by shorter variable
loops and/or a lower numbers of glycans on the viral envelope.
However, the observed changes in replication rate may also have been
selected by other mechanisms, resulting in a temporal but not a causal
relationship between HIV-1 replication capacity and molecular
characteristics of Env. Indeed, the increasing viral replication rate of
late-stage viruses in patients H2, H3, and H5 seemed to correlate
stronger with a CD4+ T-cell count below 100 cells/μl blood than with
the length or the number of PNGS in gp120. It has previously been
shown by us (Koning et al., 2003) and others (Etemad et al., 2009;
Gray et al., 2005; Jansson et al., 1996; Jansson et al., 1999; Karlsson et
al., 2004; Repits et al., 2008; Sterjovski et al., 2007) that late-stage R5
viruses evolve towards a more efﬁcient usage of CCR5. The adaptation
of HIV-1 to persist in the presence of low levels of CD4+ T cells may
thus result in an increased replication capacity (Etemad et al., 2009;
Repits et al., 2008), although we cannot exclude that the enhanced
loss of CD4+ T cells is a consequence of the increased viral replication
rate late in infection.
The selective outgrowth of virus variants with a reduced number
of PNGS and shorter variable loops in late-stage disease (Bunnik et al.,
2008) may suggest that virus replication is hindered by long variable
loops and/or an excess of glycosylation of the viral envelope when
these features are not required to protect against neutralizing
antibodies. Although our results do not support this hypothesis,
previous studies have shown that minor variations in cell growth in
the parallel cell cultures of an in vitro replication assay may prevent
the detection of relatively small differences in replication rates (van
Opijnen et al., 2004). A technique better suitable for the detection of
small differences in viral ﬁtness is a head-to-head competition assay
(van Opijnen and Berkhout, 2005). However, these competition
assays are extremely labour-intensive, especially for the large number
of viruses that were tested here (n=172). Thus, based on our results,
it cannot be excluded that escape fromNAbs exerts minor ﬁtness costs
on HIV. However, as evidence is accumulating that the development
of a broad NAb response does not protect from disease progression
(Euler et al., in press; Piantadosi et al., 2009), it seems unlikely that
such small ﬁtness costs are relevant for HIV-1 pathogenesis.
In summary, we have shown that escape from autologous humoral
immunity generally does not impair the replication kinetics of HIV-1
and will therefore not result in control of virus replication. Viral
replication kinetics may, however, be inﬂuenced by other selective
processes, such as the adaptation to a low availability of target cells in
late-stage disease.
Materials and methods
Patient and viruses
The patients in our present study were homosexual male
participants of the Amsterdam Cohort Studies on HIV infection and
AIDS (ACS) who seroconverted during active follow-up and whoprogressed to AIDS within 7–11 years after infection in the
presence of subtype B CCR5-using (R5) HIV-1 variants only, as
shown by absent virus replication in 3-monthly performed
cocultures of patient peripheral blood mononuclear cells (PBMCs)
and the MT2 cell line. For better readability, patient identiﬁers
were recoded as H1 (ACH19999), H2 (ACH19542), H3 (ACH18969),
H4 (ACH19768), and H5 (ACH19659), which correspond to the
identiﬁers used in a previous study (Bunnik et al., 2008).
Previously, we determined that patients H1, H2, and H3 developed
high-titer autologous neutralizing activity, whereas autologous
neutralizing activity was not detected in serum from H4 and H5
(Bunnik et al., 2008). From these individuals, we previously
isolated clonal HIV-1 variants from PBMCs (Schuitemaker et al.,
1992; Van 't Wout et al., 2008) that were obtained at six time
points covering the disease course from SC up to 2 to 3 years after
clinical AIDS diagnosis (Bunnik et al., 2008). For patient H5,
attempts to isolate clonal HIV-1 variants from PBMCs obtained at
SC and at time points after AIDS diagnosis were not successful. For
further study, we selected a maximum of eight virus variants per
patient per time point, representing the variation in time observed
between the start of the clonal virus isolation procedure and the
ﬁrst day of detectable p24 production in the microculture for
viruses of that time point.
Cells
Experiments were performed using cryopreserved pooled PBMCs
isolated from buffy coats obtained from 12 healthy seronegative blood
donors by Ficoll-Isopaque density gradient centrifugation. Cells were
thawed and stimulated for 3 days in IMDM (Lonza) supplemented
with 10% fetal bovine serum (FBS; Hyclone), penicillin (100 U/ml;
Invitrogen), streptomycin (100 μg/ml; Invitrogen), ciproxin (5 μg/ml;
Bayer), and phytohemagglutinin (PHA, 5 μg/ml; Oxoid) at a
concentration of 5×106 cells/ml. Subsequently, PBMCs (106/ml)
were grown in the absence of PHA, in medium supplemented with
recombinant interleukin-2 (20 U/ml; Chiron Benelux) and polybrene
(5 μg/ml, hexadimethrine bromide; Sigma).
Sequence analysis
Envs of clonal HIV-1 variants were ampliﬁed from DNA that was
isolated from in vitro infected healthy donor PBMCs. Env PCR products
were subsequently sequenced as described previously (Beaumont et
al., 2001; Boom et al., 1991; Quakkelaar et al., 2007b). Nucleotide
sequences of all virus clones per individual were aligned using
ClustalW in the software package of BioEdit (Hall, 1999) and edited
manually. Potential N-linked glycosylation sites were identiﬁed using
N-GlycoSite (Zhang et al., 2004) at the HIV databaseWeb site (http://
www.hiv.lanl.gov/content/sequence/GLYCOSITE/glycosite.html).
Coreceptor usage was predicted by PSSM based on the V3 sequences
(Brumme et al., 2004; Jensen et al., 2003), using Web PSSM at http://
indra.mullins.microbiol.washington.edu/pssm/.
Preparation of chimeric viruses
Env fragments from HXB2 nucleotides (nt) 5658 to 9171 were
ampliﬁed by PCR using Expand High Fidelity PCR System (Roche
Applied Science). Chimeric NL4-3/Env viruses were produced by
homologous recombination of the env PCR products with a pNL4-3
vector (a kind gift from P. Alcami). In short, pNL4-3 was restricted
with XbaI (HXB2 nt 6114) and XhoI (HXB2 nt 8898) and was
subsequently cotransfected with an env PCR product into 293T cells in
a 24-well plate using the calcium phosphate method. After 2 days,
PHA-stimulated PBMCs from healthy seronegative blood donors were
added to the culture, and the next day, the PBMCs were transferred to
a culture ﬂask. Supernatants were harvested when positive for p24, as
229E.M. Bunnik et al. / Virology 397 (2010) 224–230determined using an in-house p24 antigen capture enzyme-linked
immunosorbent assay (Tersmette et al., 1989). The presence of the
correct env in NL4-3 was conﬁrmed by sequencing.
Characterization of HIV-1 replication kinetics
PHA-stimulated healthy donor PBMCs (2×106) were inoculated
with 500 TCID50 of a given chimeric NL4-3/Env virus in a total volume
of 2 ml for 2 h at 37 °C in a shaking water bath. Subsequently, cells
were washed with 10 ml of IMDM supplemented with 10% FBS,
penicillin (100 U/ml), and streptomycin (100 μg/ml) and resus-
pended at a concentration of 106 cells/ml for culture. Fresh PHA-
stimulated PBMCs (106) in a volume of 1 ml were added at day 5 and
day 8. Cultures were maintained for 11 days. Samples (75 μl) for the
determination of p24 antigen production in culture supernatant were
harvested each day. The concentration of p24 in all samples was
determined at the same time using an in-house p24 antigen capture
ELISA and was used to calculate the p24 production per milliliter of
supernatant by correcting for the differences in the volumes of culture
supernatant.
Statistical analysis
Statistical analyses were performed in SPSS 16 software package.
Differences in replication rates were assessed using a t test for
independent samples. Correlations between replication kinetics and
the length or number of PNGS in Env were evaluated using the
Spearman's rank test.
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